Voices
Teclistamab

FDA Awarded a National Priority Voucher to Teclistamab with Daratumumab for R/R Multiple Myeloma

U.S. FDA shared a post on X:

“Today, the FDA awarded a national priority voucher to teclistamab in combination with daratumumab for relapsed/refractory multiple myeloma.

This brings the total number of products receiving an award under the Commissioner’s National Priority Voucher pilot program to 16.”

FDA Awarded a National Priority Voucher to Teclistamab with Daratumumab for R/R Multiple Myeloma

You can also read: MajesTEC-3 trial: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

MajesTEC-3

cancer Daratumumab FDA multiple myeloma National Priority Voucher OncoDaily Oncology R/R Multiple Myeloma teclistamab U.S. FDA